Top-Rated StocksTop-RatedNASDAQ:CRBP Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis $7.40 +0.18 (+2.42%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Corbus Pharmaceuticals Stock (NASDAQ:CRBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Corbus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$7.05▼$7.3550-Day Range$4.92▼$8.3552-Week Range$4.64▼$61.90Volume57,014 shsAverage Volume355,172 shsMarket Capitalization$90.61 millionP/E RatioN/ADividend YieldN/APrice Target$50.88Consensus RatingBuy Company OverviewCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Read More… Corbus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreCRBP MarketRank™: Corbus Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 174th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingCorbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorbus Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Corbus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($4.23) to ($6.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corbus Pharmaceuticals is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corbus Pharmaceuticals is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Corbus Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.63% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently increased by 2.16%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorbus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorbus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.65 Percentage of Shares Shorted17.63% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently increased by 2.16%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.69 News SentimentCorbus Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Corbus Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest4 people have searched for CRBP on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Corbus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Corbus Pharmaceuticals is held by insiders.Percentage Held by Institutions64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corbus Pharmaceuticals' insider trading history. Receive CRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRBP Stock News HeadlinesCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Recommendation of "Buy" from BrokeragesMay 23, 2025 | americanbankingnews.comMizuho Securities Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)May 22, 2025 | theglobeandmail.comOnly a handful of people know the setup that's defied these chaotic markets.Since February, we've hit 28 out of 29 trades – that's a 96% win rate taking simple options setups on one single ticker every day. That's why Jack Carter and I teamed up to reveal The 4PM Payout Plan. Our goal here was to show you how to take these daily setups every morning to collect a 4PM payout. Naturally, no one can guarantee what the market does in the future… But these simple daily options setups have paid out with the market rallying, dropping, or staying flat. And if you want to be one of the few to not just know the ropes behind these daily setups but also deploy them for yourself…May 29, 2025 | WealthPress (Ad)Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 22, 2025 | globenewswire.comCorbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board ChairMay 19, 2025 | finance.yahoo.comCorbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare ConferenceMay 8, 2025 | finance.yahoo.comCorbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 7, 2025 | finance.yahoo.comWe Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business GrowthApril 18, 2025 | finance.yahoo.comSee More Headlines CRBP Stock Analysis - Frequently Asked Questions How have CRBP shares performed this year? Corbus Pharmaceuticals' stock was trading at $11.80 at the start of the year. Since then, CRBP shares have decreased by 38.3% and is now trading at $7.2750. View the best growth stocks for 2025 here. How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its quarterly earnings results on Tuesday, May, 6th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.26) by $0.13. Who are Corbus Pharmaceuticals' major shareholders? Corbus Pharmaceuticals' top institutional investors include Exome Asset Management LLC (2.37%), Armistice Capital LLC (2.04%), Comerica Bank (1.63%) and Acadian Asset Management LLC (1.55%). Insiders that own company stock include Yuval Cohen, Sean F Moran and Craig Stuart Millian. View institutional ownership trends. How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Corbus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include Visa (V), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Alibaba Group (BABA) and Pfizer (PFE). Company Calendar Last Earnings5/06/2025Today5/29/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRBP CIK1595097 Webwww.corbuspharma.com Phone(617) 963-0100Fax617-663-6085Employees40Year Founded2009Price Target and Rating Average Stock Price Target$50.88 High Stock Price Target$74.00 Low Stock Price Target$35.00 Potential Upside/Downside+599.3%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($4.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$44.60 million Net MarginsN/A Pretax MarginN/A Return on Equity-42.28% Return on Assets-32.92% Debt Debt-to-Equity RatioN/A Current Ratio13.84 Quick Ratio13.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.56) per share Price / Book-4.66Miscellaneous Outstanding Shares12,237,000Free Float11,692,000Market Cap$89.02 million OptionableOptionable Beta3.19 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:CRBP) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.